Inhaled isoflurane administered by Sedaconda ACD-S + Intravenous infusion of propofol
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Intensive Care Syndrome
Conditions
Post-Intensive Care Syndrome, Sedation
Trial Timeline
Apr 22, 2022 → Jan 30, 2025
NCT ID
NCT06809218About Inhaled isoflurane administered by Sedaconda ACD-S + Intravenous infusion of propofol
Inhaled isoflurane administered by Sedaconda ACD-S + Intravenous infusion of propofol is a phase 3 stage product being developed by Brain Biotech for Post-Intensive Care Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT06809218. Target conditions include Post-Intensive Care Syndrome, Sedation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06809218 | Phase 3 | Active |